Steady dopamine, no spikes, no crashes—just one injection a week
For the roughly 8.5 million people living with Parkinson's disease, daily existence has long been measured in pills and the fragile windows between doses. Researchers at the University of South Australia have now proposed a different rhythm: a single weekly injection combining levodopa and carbidopa in a polymer matrix that dissolves steadily within the body, maintaining stable drug levels where multiple daily doses once created peaks and valleys. The work, still ahead of clinical trials, gestures toward a future in which the burden of managing an incurable disease is carried a little more lightly.
- Parkinson's patients currently face three or more daily doses of levodopa, and missed or inconsistent doses cause motor symptoms to deteriorate sharply — a daily tightrope walk for millions, especially the elderly.
- Australian scientists have engineered a polymer blend of PLGA and Eudragit that, once injected, forms an implant inside the body and releases levodopa and carbidopa at a controlled rate across seven full days.
- Laboratory results are striking: more than 90 percent of the levodopa dose and more than 81 percent of the carbidopa dose released on schedule, the implant degraded completely within a week, and cell toxicity tests showed no significant harm.
- The formulation can be delivered through a standard needle — no surgery, no removal procedure — sidestepping the practical obstacles that have limited previous long-acting injectable approaches.
- Clinical trials have not yet begun, but if human testing confirms the laboratory findings, this weekly injection could replace the daily pill regimen that currently defines — and burdens — Parkinson's care worldwide.
Researchers at the University of South Australia have developed a weekly injection that could fundamentally change how Parkinson's disease is managed. The formulation combines levodopa and carbidopa — the two drugs at the core of current treatment — into a slow-release system that sustains therapeutic drug levels in the bloodstream for seven days from a single dose.
Parkinson's destroys the brain's dopamine-producing neurons, affecting around 8.5 million people globally. Levodopa remains the most effective symptomatic treatment available, but its short half-life forces patients to dose three or more times daily. For elderly patients and those with swallowing difficulties, maintaining that schedule is genuinely hard. When doses are missed, plasma concentrations swing unpredictably, and symptoms worsen in the gaps.
The new system uses two biodegradable polymers — PLGA and Eudragit L-100 — that form a matrix after injection and dissolve gradually, releasing both drugs at a controlled rate. The optimized blend can be administered through a standard 22-gauge needle, requiring no surgical implant or later removal. In laboratory testing, more than 90 percent of the levodopa and more than 81 percent of the carbidopa released over seven days, with complete degradation of the implant and no significant toxicity detected.
Published in Drug Delivery and Translational Research, the work addresses a gap that previous long-acting injectable technologies — microparticles, liposomes, solid implants — struggled to fill, each carrying its own practical limitations around drug capacity, dosing accuracy, or the need for surgery. The in-situ approach avoids those obstacles by forming and dissolving entirely within the body on a weekly cycle.
The clinical implications, if human trials confirm the laboratory results, are considerable. Stable plasma levels would reduce the unpredictable on-off motor fluctuations that disrupt daily life, while weekly dosing would ease the compliance burden that weighs most heavily on older patients. The technology has not yet entered clinical trials, but the trajectory points toward a meaningful shift in the daily reality of living with an incurable disease.
Australian researchers at the University of South Australia have engineered a weekly injection that could reshape how millions of Parkinson's patients manage their disease. The breakthrough combines two established medications—levodopa and carbidopa—into a long-acting formulation that releases steadily over seven days, eliminating the need for multiple daily pills that currently define treatment for this progressive neurological disorder.
Parkinson's disease destroys dopamine-producing neurons in the brain, affecting roughly 8.5 million people worldwide. It is the second most common neurological disorder globally, and there is no cure. Levodopa, approved decades ago, remains the most effective symptomatic treatment. The drug crosses the blood-brain barrier and converts to dopamine in the brain, restoring some motor function. But levodopa has a short half-life, meaning it breaks down quickly in the body. Patients must take it multiple times daily—typically three or more doses—to maintain therapeutic levels. This burden falls hardest on the elderly and those with swallowing difficulties, who struggle with pill adherence. When doses are missed or inconsistent, plasma concentrations fluctuate wildly, causing the symptoms to worsen between doses.
The new injectable system addresses this directly. Researchers formulated the drugs using two polymers: PLGA (polylactic-co-glycolic acid) and Eudragit L-100. These materials dissolve gradually in the body, releasing levodopa and carbidopa at a controlled rate. The optimized formulation—containing 26 percent PLGA and 6 percent Eudragit—achieved a favorable release profile and could be injected through a standard 22-gauge needle, avoiding the need for surgical implantation. In laboratory testing, more than 90 percent of the levodopa dose and more than 81 percent of the carbidopa dose released over seven days. The implant degraded completely within a week and showed no significant toxicity in cell viability tests.
The work, published in Drug Delivery and Translational Research, represents a shift in how long-acting injectables can be delivered. Previous approaches—microparticles, liposomes, solid implants—faced practical obstacles: limited drug capacity, uneven distribution affecting dosing accuracy, and the need for surgery to remove implants. The in-situ system sidesteps these problems. A patient receives a simple injection once weekly. The polymer matrix forms in the body and dissolves on schedule, maintaining steady drug levels in the bloodstream.
For Parkinson's patients, the implications are substantial. Stable plasma concentrations mean fewer motor fluctuations—the unpredictable on-off cycles that disrupt daily life. Reduced dosing frequency improves compliance, particularly among older adults who struggle with complex medication schedules. The approach also minimizes side effects tied to concentration spikes and troughs. Carbidopa, which prevents levodopa from breaking down in the periphery before reaching the brain, is delivered in tandem, maintaining the fixed-dose combination that has proven most effective.
Parkinson's disease is progressive and incurable. Current oral treatments, even sustained-release formulations, require multiple administrations daily. This new injectable offers an alternative pathway: sustained drug delivery with constant plasma levels, fewer doses, and lower side-effect burden. The technology is not yet in clinical trials, but the laboratory results suggest it could move toward human testing. If it does, the weekly injection could become standard care, transforming the daily reality for millions of patients who have managed their disease one pill at a time.
Notable Quotes
The weekly injection provides sustained drug release with constant plasma levels while reducing dosing frequency and side effects— University of South Australia researchers
The Hearth Conversation Another angle on the story
Why does it matter that levodopa has a short half-life? Couldn't patients just take a larger dose less often?
Because the brain doesn't work that way. Dopamine levels need to stay relatively stable. If you take one large dose, you get a spike—tremors improve, movement becomes fluid—then it crashes, and symptoms roar back. Patients call it the on-off effect. It's exhausting and unpredictable.
So the polymer injection keeps the drug level constant?
Exactly. The PLGA and Eudragit dissolve slowly and predictably over a week. No spikes, no crashes. Just steady dopamine replacement.
Why hasn't this been done before?
It has, in other diseases. But getting the chemistry right for Parkinson's—the right polymer blend, the right release rate, the right needle gauge—took time. And you have to prove it's safe and that it actually works in people, not just in the lab.
Who benefits most?
Elderly patients, mainly. Someone in their seventies managing Parkinson's and arthritis and hypertension—remembering to take levodopa three times a day is genuinely hard. One injection a week? That changes everything.
What's the next step?
Clinical trials. They need to test it in actual patients, watch for side effects, confirm the release profile holds up in living bodies. That's years away.
And if it works?
It becomes the standard. You go from daily pills to weekly injections. For 8.5 million people, that's a significant shift in quality of life.